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INTRODUCTION
Hypercholesterolemia is a major underlying cause for ischemic stroke and therapeutics targeting hypercholesterolemia decrease the risk of stroke in high-risk individuals or in patients with stroke or transient ischemic attack (Amarenco and Labreuche, 2009 ).
Although cerebral ischemia commonly occurs in patients with hypercholesterolemia, studies have been hampered in part because the vessels are smaller and more difficult to access. In contrast, larger arteries such as the aorta and peripheral arteries have been extensively studied (Ross, 1999) . In systemic vessels in humans and in animal models, hypercholesterolemia impairs endothelial and smooth muscle function (d'Uscio et al., 2001; Casino et al., 1993) . Therefore, the effects of lipid lowing drugs on cerebrovascular function and pathogenic mechanisms of ischemic stroke with hypercholesterolemia should be fully elucidated in vivo.
Probucol is a potent lipid-soluble antioxidant that possesses anti-atherogenic properties (Kuzuya and Kuzuya, 1993) and prevents secondary cardiovascular events in patients with hypercholesterolemia (Yamashita et al., 2008) . Cilostazol inhibits platelet aggregation by inhibiting the activity of phosphodiesterase III and has a demonstrated neuroprotective effect against cerebral ischemic injury in experimental studies (Choi et al., 2002; Lee et al., 2007) and clinical studies (Shinohara et al., 2010) .
In seeking to maximize the effects of these beneficial and useful drugs, it has been suggested that their combinatorial application might reduce atherosclerosis and prevent ischemic damage. The combinatorial strategy is supported by results of a clinical study regarding restenosis (Sekiya et al., 1998) and in vitro and in vivo experimental studies regarding atherosclerosis (Park et al., 2008; Yoshikawa et al., 2008) . Moreover, concurrent treatment with probucol and cilostazol produced beneficial synergistic effects against focal cerebral ischemic injury in a rat model by reducing the This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on May 5, 2011 as DOI: 10.1124 at ASPET Journals on April 12, 2017 jpet.aspetjournals.org Downloaded from JPET #181180 5 generation of superoxide (Park et al., 2007) . With the aim of developing a more effective therapeutic window in the focal ischemic brain injury with hypercholesterolemia, the present study was undertaken to examine the efficacy of probucol and cilostazol combinatorial therapy.
The exact mechanisms of cerebrovascular dysfunction to ischemia during hypercholesterolemia are not completely defined but may include reduction in endothelial nitric oxide production. It has been reported that ApoE knock-out (KO) mice fed a high-fat Western diet (HFD) display endothelial dysfunction via impairment of endothelial nitric oxide synthase (eNOS)-dependent vasorelaxation (d'Uscio et al., 2001) . eNOS contributes to vascular protection via increasing cerebral blood flow (CBF) and plays an important role in the regulation of brain damage after ischemia (Endres et al., 1998) and adiponectin prevents cerebral ischemic injury through eNOSdependent mechanism (Nishimura et al., 2008) . Thus, agents that regulate adiponectin-mediated eNOS signaling and increase CBF could represent a potential therapeutic target for the prevention of ischemic stroke with hypercholesterolemia.
In the present study, we explored the effects of the combinatorial use of probucol and cilostazol on focal cerebral ischemia with hypercholesterolemia using HFD-fed ApoE KO mice as an animal model. The tissue and neurologic outcomes were determined following transient middle cerebral artery (MCA) occlusion in ApoE KO mice fed the HFD for 10 weeks using treatment with probucol and cilostazol. CBF and eNOS expression levels in accordance with adiponectin expression levels were determined as the action mechanisms. The study presents evidence-based cerebrovascular protective effects of combinatorial therapy with probucol and cilostazol on the management of stroke patients who undergo hypercholesterolemia. 
METHODS
General surgical preparation
Male ApoE KO mice (Japan SLC, Shizuoka, Japan) having a C57BL/6J genetic background were housed under diurnal lighting conditions and allowed food and tap water ad libitum. All animal procedures were in accordance with the institutional guidelines for animal research, and had been approved by the university Animal Care and Use Committee. Four-week-old ApoE KO mice were fed a Western-type HFD (42% of total calories from fat; 0.15% cholesterol; Research Diet, New Brunswick, NJ) containing 0.5% (wt/wt) probucol, 0.2% (wt/wt) cilostazol or 0.5% (wt/wt) probucol + 0.2% (wt/wt) cilostazol for 10 weeks. Anesthesia was achieved by isoflurane (2% induction and 1.5% maintenance, in 80% N 2 O and 20% O 2 ) by face mask. The femoral artery was catheterized for the measurement of mean arterial blood pressure using a model MLT844 physiological pressure transducer (AD Instruments, Medford, MA). The data were continuously recorded using a PowerLab data acquisition and analysis system (AD Instruments) and stored in a computer. The depth of anesthesia was checked by the absence of cardiovascular changes in response to tail pinch. Rectal temperature was kept at 36.5°C-37.5°C using a Panlab TM thermostatically controlled heating mat (Harvard apparatus, Holliston, MA). Arterial blood gases and pH were measured before ischemia using i-Stat System (Abbott, Abott Park, IL).
Measurement of plasma cholesterol
Blood was collected from the left ventricle under light anesthesia and stored on ice for 30 min prior to centrifugation at 13,000 rpm, 4ºC for 10 min, the plasma separated and kept at -80ºC until assayed. Lipoprotein cholesterol distribution of plasma samples was 
Atherosclerotic lesion analysis
After 10 weeks of the HFD, mice were anesthetized and euthanized. Hearts were perfused using 10 ml of phosphate buffered saline (PBS) followed by 10 ml of 4% 
Focal cerebral ischemia
A fiber-optic probe was affixed to the skull over the middle cerebral artery (MCA) for measurement of regional CBF (rCBF) by a PeriFlux Laser Doppler System 5000 (Perimed, Stockholm, Sweden). Baseline values were measured before internal carotid artery ligation (considered to be 100% flow). Focal cerebral ischemia was induced by occluding the MCA by a previously described intraluminal filament technique (Huang et al., 1994) . MCA occlusion was induced by a silicon-coated 7-0 monofilament in the internal carotid artery and the monofilament was advanced to occlude the MCA. In all animals, rCBF was measured to confirm the achievement of consistent and similar levels of ischemic induction. The filament was withdrawn 60 min after occlusion and 
Neurological score
Neurological deficit was scored in each mouse at 24 h after the ischemic insult in a blinded fashion according to the following graded scoring system: 0 = no deficit; 1 = forelimb weakness and torso turning to the ipsilateral side when held by tail; 2 = circling to affected side; 3 = unable to bear weight on affected side; and 4 = no spontaneous locomotor activity or barrel rolling (Li et al., 2004) .
Immunofluorescence
Twenty four hours after MCA occlusion, mice were deeply anesthetized with thiopental sodium and subsequently perfused transcardially with cold PBS followed by 4% paraformaldehyde for fixation. The brain of each mouse was then removed and further fixed for 48 h in 4% paraformaldehyde at 4ºC followed by cryoprotection in 20%
sucrose for 24 h at 4ºC. The isolated brains were frozen and stored in the freezer at - 
Drugs
Probucol [4,4'-(isopropylidenedithio)bis(2,6-di-t-butylophenol)] and cilostazol [OPC-
were donated by Otsuka Pharmaceutical (Tokushima, Japan) and were added to the HFD.
Data analysis
The data are expressed as mean ± standard error of mean (SEM). Control vs. vehicle group was compared by unpaired t-test. Vehicle vs. drug alone treated groups or combinatorial group were compared using Dunnett's test. Pearson's correlation coefficient was calculated between infarct volume and total cholesterol level. The differences were considered statistically significant, when the two-tailed p values were less than 0.05. Statistical analysis was performed using SAS software (SAS Institute Japan, R9.1).
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RESULTS
Physiological parameters and plasma lipid profiles
The body weights of ApoE KO mice fed a HFD for 10 weeks were slightly higher than those in normal diet-fed mice (control) (25.90±0.97 g vs 32.39±0.71 g, respectively,
P<0.01). Probucol and/or cilostazol did not affect body weight of HFD-fed mice ( Table   1 ). The blood pressure did not differ among mice treated with probucol and/or cilostazol.
After 10 weeks of the HFD, large increases in plasma total cholesterol and low density lipoprotein (LDL) cholesterol were observed in ApoE KO mice ( (Figure 1) . Moreover, when the two agents were administered in combination, the atherosclerotic lesions were more potently inhibited (4.04±1.58 mm 2 , P<0.01).
Effect of combinatorial therapy on infarct size and neurological deficit
In order to determine whether combinatorial therapy improved the tissue outcome during cerebral ischemia in hypercholesterolemic mice, the infarct size was measured 23 h after a 1-h transient MCA occlusion. MCA occlusion resulted in 76% larger infarct Figure 2C ). There was a positive correlation between plasma total cholesterol levels and infarct size after probucol treatment, and this positive correlation was noted when probucol was administered with cilostazol (data not shown). Since an increase in CBF protects against stroke, the changes in CBF during ischemia were assessed. When the CBF time course in MCA was measured, MCA occlusion was revealed to cause an abrupt reduction in CBF and CBF was higher in combination treated-mice than in age-and diet-matched ApoE KO mice, suggesting that combinatorial treatment of probucol and cilostazol lead to increased CBF during ischemia.
Effect of combinatorial therapy on eNOS and adiponectin expression
In order to explore the action mechanisms of combinatorial treatment of probucol and cilostazol on focal cerebral ischemia with hypercholesterolemia, we studied eNOS expression level in accordance with adiponectin expression levels. Few eNOS-and adiponectin-positive cells were observed in the vehicle group ( Figures 4A and 4B ).
eNOS-and adiponectin-positive cells were increased in mice that received probucol and cilostazol in combination, whereas probucol alone or cilostazol alone showed only marginal effects on eNOS and adiponectin expression, indicating the beneficial effects of the combinatorial therapy. In addition, cilostazol alone or combinatorial treatment increased CD31, an endothelial cell marker ( Figure 4B ). Dual-immunofluorescence staining was performed on adiponectin (red) and CD31 (green) and merged images demonstrated that these proteins co-localized (yellow) ( Figure 4C ). Collectively, these data support the suggestion that adiponectin accumulates at the endothelium in the cortex. dyslipidemia (high total cholesterol and LDL cholesterol levels, and low high density lipoprotein (HDL) cholesterol level) and stroke (Tanne et al., 2001; Jurgens et al., 1995) , while other studies have not identified such an association (Sacco et al., 2001; Tanizaki et al., 2000) . Few studies have evaluated ischemic stroke subtypes and patient subgroups (Tirschwell et al., 2004) . Cholesterol-lowering trials have shown a decrease in the risk of cerebral infarction among patients assigned to statin treatment (White et al., 2000) . In the present study, 1 h MCA occlusion and 23 h reperfusion resulted in significantly larger infarct volumes by 76% in ApoE KO fed a HFD for 10 weeks compared to ApoE KO on regular diet, consistent with a previous report (Mogi et al., 2006) . This larger infarct volume was significantly reduced in accordance with significantly decreased cholesterol levels and atherosclerotic lesion areas in the aorta by probucol alone or by a combinatorial treatment of probucol and cilostazol. Taking into consideration the association between the infarct volume after MCA occlusion and serum lipid profile (total cholesterol), there was a positive linear relationship (r=0.77,
DISCUSSION
P<0
.01) in control, vehicle, probucol alone and the combinatorial groups. When we observed Oil red O staining in cerebral arteries of ApoE KO fed a HFD for 10 weeks, no atherosclerotic lesions were observed in cerebral arteries (data not shown). Therefore, we believed that the increase in ischemic brain damage in ApoE KO fed a HFD may not be due directly to the structure of cerebral arteries by atherosclerotic plaque formation.
Lipid lowering therapy significantly reduces the risk of stroke (Collins et al., 2003) .
In part, this improved outcome has been attributed to a slowed progression of intracranial (carotid) atherosclerosis consequent to a decrease in hypercholesterolemia (Amarenco and Labreuche, 2009 beneficial effects of statin in stroke may be due only in part to lipid-lowering properties, with the primary benefit derived from improved endothelial function as well as the antiinflammatory and anti-thrombotic actions of the drugs (Vaughan et al., 2001; Ishikawa et al., 2004) . Probucol (0.5%) and cilostazol (0.2%) treatment significantly decreased total cholesterol and LDL cholesterol levels, and ameliorated the progression of atheroma formation in the entire aorta in ApoE KO mice fed with the HFD. A clinical study (Sekiya et al., 1998) and experimental studies (Yoshikawa et al., 2008) have suggested the potential beneficial effects of probucol and cilostazol on restenosis and atherosclerosis. In LDL receptor-deficient mice, the combination of probucol and cilostazol more significantly decreased the atherosclerotic lesion area than either probucol or cilostazol alone (Yoshikawa et al., 2008) . The clinical study resulted that treatment with a combination of probucol and cilostazol was safe and effective in preventing acute post-stenting complications and suppressing chronic restenosis (Sekiya et al., 1998) . Presently, the combinatorial treatment with probucol and cilostazol modulated plasma cholesterol levels. It is possible that these effects may have inhibited atherosclerotic lesions and stroke development in ApoE KO mice fed the HFD.
Both probucol and cilostazol have been approved for use. Both are safe and efficient in their respective therapeutic categories with some different and similar action mechanisms. Probucol, which is a potent lipid-soluble antioxidant, possesses antiatherogenic properties (Kuzuya and Kuzuya, 1993) . Cilostazol increases intracellular cyclic AMP levels by inhibiting type III phosphodiesterase, and has a demonstrated in vivo neuroprotective effect against cerebral ischemic injury via anti-apoptotic and antiinflammatory effects (Choi et al., 2002; Lee et al., 2007) . Moreover, cilostazol has been shown to increase plasma HDL cholesterol levels and inhibit atherosclerosis formation in ApoE KO mice fed with a Western diet and LDL receptor-deficient mice fed with a HFD (da Rosa et al., 2006; Lee et al., 2005) . It is likely that two drugs that possess different mechanisms of action may result in an effective therapy. In the previous in vitro study, we assessed the synergistic efficacy of the combinatorial therapy with probucol and cilostazol on the antioxidant and anti-inflammatory actions in cultured human coronary artery endothelial cells (Park et al., 2008) . Concurrent treatment with probucol and cilostazol had beneficial synergistic effects against focal cerebral ischemic injury in rats via reduced superoxide generation (Park et al., 2007) .
Consistent with these reports, we presently observed that a combinatorial therapy of probucol and cilostazol reduced infarct size with neurological deficits, providing a potential strategy for preventing ischemic stroke with hypercholesterolemia. In addition, cilostazol alone or combinatorial treatment accelerated angiogenesis which is evidenced by increased microvessels (CD31 staining, Figure 4B ). Our results are consistent with the reported findings that long-term treatment of cilostazol increased angiogenesis which can increase CBF and improve brain tissue recovery (Ye et al., 2007) . Therefore, additional use of cilostazol could improve brain tissue recovery and functional recovery in addition to antioxidant action of probucol.
Hypercholesterolemia is associated with decreased nitric oxide (NO) bioavailability and endothelial dysfunction, which may be very important in the altered CBF evident in stroke. Endothelial dysfunction via impairment of eNOS-dependent vasorelaxation in the aorta, carotid artery, and cerebral arterioles of ApoE KO mice fed a HFD has been reported (d'Uscio et al., 2001) , and also in the forearm and coronary arteries of hypercholesterolemic patients (Casino et al., 1993) . Endothelial NOS and vascular NO maintain CBF and protect against brain injury after ischemia (Endres et al., 1998) .
Probucol improves the endothelium-dependent relaxation in aortic balloon injury in rabbits and a swine model of left ventricular hypertrophy by increasing NO-mediated vasodilation (Lau et al., 2003) . Additionally, cilostazol causes vasodilation through an endothelial-NO-dependent pathway in rat aorta (Nakamura et al., 2001 ) and increases the phosphorylation of eNOS at Ser1177 in human aortic endothelial cells (Hashimoto et al., 2006) . In this study, we observed an increase in CBF by combinatorial treatment with probucol and cilostazol during cerebral ischemia in ApoE KO mice fed a HFD.
Moreover, hypercholesterolemia down-regulated eNOS and adiponectin in the cortex and these effects were increased by the combinatorial long-term application of probucol and cilostazol. However, we could not observe the changes of phosphorylated eNOS by combinatorial treatment with probucol and cilostazol (data not shown),
suggesting that probucol and cilostazol treatment do not activate eNOS acutely by post-translational modification including phosphorylation which is approach for acute stroke treatment. We suggested that long-term probucol and cilostazol treatment leads to upregulation of eNOS, which has a combined effect of stroke prevention and prophylactic treatment for ischemic stroke with hypercholesterolemia.
Adiponectin exerts beneficial actions on cerebrovascular disease. Adiponectin is cerebroprotective by an eNOS-dependent mechanism (Nishimura et al., 2008) .
Adiponectin KO mice develop impaired ischemia-induced angiogenesis in a mouse model of vascular insufficiency and an excessive vascular remodeling response to injury (Matsuda et al., 2002) . Recent results of a clinical study suggested an association between hypoadiponectinemia and increased mortality after ischemic stroke, and a negative correlation between adiponectin levels and initial infarct volume JPET #181180
1 7 (Chen et al., 2005) . As well, hyperadiponectinemia is neuroprotective against ischemic stroke (Ouchi et al., 2003) . Furthermore, adiponectin accumulates in the vascular endothelium during cerebral ischemia (Nishimura et al., 2008) . Thus, agents that increase circulating adiponectin levels could represent a potential therapeutic target for the prevention of ischemic stroke. Probucol can significantly elevate serum adiponectin concentrations in diabetic rats (Zhang et al., 2009 ) and cilostazol increases adiponectin levels in type 2 diabetic patients and in a diabetic animal model (Hsieh and Wang, 2009 ). In the present study, the accumulation of adiponectin with eNOS in the vasculature in the combinatorial therapy group may have served to protect the vasculature. Collectively, these observations suggest that the combinatorial treatment with probucol and cilostazol regulates the adiponectin-eNOS signaling axis functions to modulate vascular function, protecting against cerebral injury after stroke.
In summary, the combinatorial therapy with probucol and cilostazol prevents ischemic stroke with hypercholesterolemia through an increase of CBF via an increase of eNOS and adiponectin. This finding may provide convincing evidence to support the cerebrovascular protective effects of the combinatorial therapy on the focal cerebral ischemic injury with hypercholesterolemia.
